Clinical Trial Update: Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial [Phase 2]

View source ↗

Summary

Phase II trial evaluating almonertinib as upfront treatment for uncommon EGFR mutation–harboring non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN